Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
The enigma of sepsis
Niels C. Riedemann, … , Ren-Feng Guo, Peter A. Ward
Niels C. Riedemann, … , Ren-Feng Guo, Peter A. Ward
Published August 15, 2003
Citation Information: J Clin Invest. 2003;112(4):460-467. https://doi.org/10.1172/JCI19523.
View: Text | PDF
Science in Medicine

The enigma of sepsis

  • Text
  • PDF
Abstract

Sepsis remains a serious cause of morbidity and mortality, and the pathophysiology of the disease is not clear. The definition of the clinical manifestations of sepsis is ever evolving. This review discusses the search for effective therapeutic interventions, hurdles in translational sepsis research, and new therapies in development in current clinical trials.

Authors

Niels C. Riedemann, Ren-Feng Guo, Peter A. Ward

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Possible reasons for failure in sepsis trials. The flow diagram reflects...
Possible reasons for failure in sepsis trials. The flow diagram reflects various stages in the development of sepsis therapies that precede clinical trials in sepsis patients. At each stage, possible reasons for failure of the strategy are listed. The murine LPS infusion model illustrates that anti–TNF-α antibody treatment can successfully increase survival rates of septic animals; however, this same therapy proved unsuccessful in clinical trials in humans with sepsis.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts